Micro Emerging Active

IMCR downgraded by Jefferies due to clinical trial setback

Score
0.2
Velocity
▲ 0.0
Articles
1
Sources
1

Summary

An article belongs to this narrative if it discusses Immunocore's stock downgrade due to clinical trial results.

Related Articles

Jefferies Downgrades Immunocore Holdings plc (IMCR) to Hold with a $33 Price Target

Yahoo Finance · Mar 25, 2026
Mixed

Sources

Jefferies Downgrades Immunocore Holdings plc (IMCR) to Hold with a … Yahoo Finance

Timeline

Last Updated Mar 25, 2026